Named prescribers, with numbers you can look up
Two physicians are identified by name and NPI. That is the difference between a disclosure a reader can verify in a federal registry and a claim about board-certified providers that cannot be checked at all, and the second kind is what almost everyone in this category offers.
The medical group behind the service is named as well. Taken together it means a reader can establish who is responsible for the prescription before they hand over a health history, which is a low bar this category mostly fails.
Six pharmacies, and what naming them revealed
The frequently asked questions list six partner pharmacies with a telephone number and a website for each. Most sellers here name none.
That disclosure has a consequence Renn presumably did not intend. Because the pharmacies are named, they can be screened, and one of them appears in the FDA warning-letter record: a 2023 letter whose recipient line names the pharmacy at its Colorado address, describing an inspection of an affiliated facility in Florida. The letter belongs to that pharmacy and not to Renn, and it is disclosed here on that basis rather than scored against this row. It is also the argument for naming a pharmacy rather than describing one, since a pharmacy nobody can name is a pharmacy nobody can check.
The prices are floors
Both figures are as-low-as prices. Neither carries a dose, and the product pages do not say how far the number moves as the dose climbs. The homepage names a bundle discount structure for three and six month commitments and does not price the bundles.
So the disclosure quality on sourcing is not matched on price. A reader can find out who prescribes and who dispenses, and cannot find out what a maintenance month costs.
Coverage and the rest
The service states it serves patients in all fifty states while saying plainly that availability of specific services can vary with provider licensure. Stating the caveat rather than only the claim is the right way round.
The offer is described as a subscription with predictable monthly pricing and no hidden fees, so the plan charge is the whole bill and no separate membership is named. Everything offered is compounded, with no brand-name route.
Renn's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $149/moas low as, per month — the sellers own words; the homepage describes the model as predictable monthly pricing with three and six month bundles carrying stack discounts | September 2026source |
| Tirzepatide (compounded) | $199/moas low as, per month — the sellers own words; no plan term or bundle condition is printed beside the figure on the product page | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See Renn's current price →Good fit if
- Readers who will not enrol without knowing which clinician prescribes and which pharmacy dispenses.
- Patients who want to verify a prescriber independently, which the published NPI numbers make possible.
- Anyone in a smaller market, given the stated fifty-state footprint.
- Readers who want the subscription charge to be the whole bill rather than one component of it.
Look elsewhere if
- Anyone who needs to know what a maintenance dose costs; both figures are floors with no dose attached.
- Patients uncomfortable with a pharmacy network in which one named member holds an FDA warning letter.
- Readers comparing bundle pricing, which the site names but does not price.
- Anyone who wants a brand-name, FDA-approved GLP-1.
How this review was verified
- Read the homepage and both GLP-1 product pages at their source URLs and logged each figure with the date it was read.
- Carried the seller's own as-low-as language into each qualifier rather than presenting either figure as a rate.
- Took the two prescriber names and NPI numbers, and all six pharmacy names, verbatim from the published questions and answers.
- Screened every named pharmacy against the FDA warning-letter record separately from the brand, fetched the one letter that matched, and confirmed its recipient line and address before recording it as belonging to that pharmacy rather than to this seller.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter for the brand or its medical group.